GlassScriptPhysician profile
James M Steier
NPI 1982675518
$4,491.44
in general payments reported to CMS, 2019-2025
42 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $515 · 2020: $144 · 2021: $1,149 · 2022: $967 · 2023: $915 · 2024: $461 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,716.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $863.46 | 2019-2024 | Qulipta, Ubrelvy, Linzess |
| Amgen INC. | $423.80 | 2019-2023 | Prolia, Evenity |
| Lilly USA, LLC | $318.32 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $282.13 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.22 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $266.63 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $247.33 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $167.52 | 2022-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $165.66 | 2021-2025 | |
| Amarin Pharma, INC. | $142.40 | 2019-2021 | |
| Boston Scientific Corporation | $123.67 | 2019-2025 | Watchman Flx, Watchman Access System |
| Sanofi-Aventis U.S. LLC | $114.71 | 2020-2024 | |
| Astellas Pharma US INC | $108.32 | 2019-2022 | |
| Gilead Sciences, INC. | $105.91 | 2019-2025 | |
| Daiichi Sankyo INC. | $76.45 | 2021-2023 | Injectafer |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Steier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.